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In-stent restenosis (ISR) often occurs after applying drug eluting stents to the blood vessels suffering 
from atherosclerosis or thrombosis. For treatment of ISR, drug eluting balloons (DEB) have been 
developed to deliver anti-proliferative drugs to the lesions with ISR. However, there are still limitations 
of DEB such as low drug delivery efficiency and drug loss to blood flow. Although most researches 
have focused on alteration of drug formulation for more efficient drug delivery, there are few studies 
that have attempted to understand and utilize the contact modality of DEB drug delivery. Here, we 
developed a linear micro-patterned DEB (LMDEB) that applied higher contact pressure to enhance 
drug stamping to vascular tissue. Ex vivo and in vivo studies confirmed that higher contact pressure 
from micro-patterns increased the amount of drug delivered to the deeper regions of vessel. Finite 
element method simulation also showed significant increase of contact pressure between endothelium 
and micro-patterns. Quantitative analysis by high performance liquid chromatography indicated that 
LMDEBs delivered 2.3 times higher amount of drug to vascular tissue in vivo than conventional DEBs. 
Finally, efficacy studies using both atherosclerotic and ISR models demonstrated superior patency of 
diseased vessels treated with LMDEB compared to those treated with DEB.
To treat coronary or peripheral vascular disease, many advances have been made in the field of percutaneous 
coronary intervention, ranging from balloon angioplasty to drug eluting stent (DES)1–3. These technologies were 
developed mainly to reduce restenosis rates after interventions. Although DES has been a standard treatment for 
patients with vascular occlusion or thrombosis4,5, in-stent restenosis (ISR) often followed stent treatment as an 
inevitable adverse consequence6.
Coating of polymeric matrix containing anti-proliferative drug on the surface of DES significantly reduces ISR 
occurrence. However, the degradation and endocytosis of the coating formulation of DES often induce inflam-
mation and thrombosis that can lead to restenosis7. There have been a number of treatments for ISR including 
balloon angioplasty, implantation of a second stent, rotablation, and brachytherapy8–12. However, since the first 
clinical trial of drug eluting balloon (DEB) for treatment of ISR in human13, DEB has shown encouraging out-
comes and is recommended as a guideline against ISR from prominent societies of medical professions14,15.
In recent years, formulations of drug coating of DEBs have been extensively investigated for efficient delivery 
of an anti-proliferative drug, paclitaxel. The most representative coating methods for DEB are PACCOCATH® 
(Oberpfaffenhfen, Germany) and DIOR® (Bonn, Germany) technology16–18. The PACCOCATH® uses iopromide 
as a hydrophilic spacer coating that has porous structure with high contact efficiency between the vessel lesion 
and the lipophilic paclitaxel (PTX)16. DIOR® has a coating layer of a mixture of PTX and shellac on the rough-
ened surface of a DEB without matrix polymer. This characteristic achieves higher bioavailability of the paclitaxel 
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and efficient delivery to the lesion upon inflation16,19. For enhanced local drug delivery, balloon structures were 
also modified using double balloons or porous surfaces20,21.
There, however, are still common limitations of the current DEB technologies relating endovascular drug 
delivery efficiency22,23. For sufficient release of drug, DEB dilation is maintained for 60 seconds to make a contact 
with a vascular lesion. Due to this prolonged blockage of vessels, the use of DEB is not recommended for patients 
who are vulnerable to additional complications. More importantly, although DEB drug delivery depends only 
on a short contact between a drug-coated balloon and a vascular lesion, the drug transfer mechanism is poorly 
understood. The drug delivery efficiency of a DEB is generally low, and more systematic investigation is necessary 
to understand how drug molecules are transferred from a DEB surface to target tissue lesion during their contact. 
Loss of drug during balloon handling and insertion through catheters to the target lesion is also significant. The 
coated drug can also be washed off of the DEB surfaces due to a highly viscous blood stream.
The fundamentals of drug adsorption from DEB to lumen surface are based on a combination of multi-
ple modes of interactions such as electrostatic interaction, van der Waals force, and entropic effects between 
drug coating and endothelium on a molecular scale24,25. Thus, most DEB studies to enhance the efficiency of 
drug adhesion have relied on methods such as modulation of hydrophilic drug carriers for delivering lipophilic 
anti-proliferative drugs to the lesion lumen13–17,19. However, a firm contact between the surface of inflated balloon 
and lumen is a critical prerequisite for sufficient drug adsorption onto the target tissue in the lumen surface to 
occur. Compared to the flat surface of conventional DEBs, it is anticipated that the use of micro-patterned surface 
may provide a firm contact and increase a contact pressure in particular for soft and deformable tissue like blood 
vessels. Although such enhanced contact and higher pressure from micro-patterned DEBs are likely to increase 
the efficiency of drug delivery, there has been no attempt of investigating the effect of micro-patterned DEBs yet.
Herein, we propose a linearly micro-patterned drug eluting balloon (LMDEB) to enhance the efficiency and 
accuracy of endovascular drug delivery to a target lesion by increasing contact pressure between the coating 
and inner vessel wall. LMDEBs were fabricated using a commercial manufacturing balloon forming machine 
based on a blow molding process with micro-machined balloon forming molds. Prior to conventional balloon 
angioplasty with DEB for endovascular drug delivery, the diameter of lesion vessel is inflated 1.3 times using a 
non-coated balloon catheter, which is a standard procedure for any DEB intervention. Then, as shown in Fig. 1, 
LMDEB becomes inflated up to a size equivalent to the enlarged diameter of the pre-stretched lesion vessel. 
During this inflation, the LMDEB forms more localized contacts with the luminal side of the vascular tissue. 
Figure 1. Schematic of linear micro-patterned drug eluting balloon (LMDEB) application to the stenosis 
lesion of blood vessel. Enhancement of drug delivery by increasing contact pressure at micro-patterns after full 
inflation.
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This induces higher contact pressure and more efficient “drug stamping” on the target lesion than DEBs without 
micro-patterns.
Results
Fabrication of LMDEB. LMDEBs were fabricated by the following process; thin cylinder tubes made of 
polyether block amide elastomer (PEBAX) were blow-molded in a micro-machined balloon forming mold. The 
micro-machined mold was fabricated by an electric discharge machining (EDM) wire-cut process to have a lin-
ear array of intaglio linear micro-patterns (LMs) on the inner surface of the mold. The widths and intervals of 
the LMs were determined by the limitation of EDM wire-cut process for mold fabrication. We hypothesized 
that wider widths and intervals would decrease the contact pressure. Therefore, the width and intervals were 
the smallest that could be fabricated by the EDM process, in an effort to increase contact pressure (in Fig. 2A). 
We also hypothesized that taller micropatterns would be more beneficial in achieving focused contact with the 
endothelium. Therefore, the height (130 μm) of the micropatterns with round tips at uniform intervals of 22.5° 
was the tallest that we could achieve from our balloon molding process as shown in Fig. 2B. The thickness of the 
finished LMDEB was about 25 µm, and the dimension of LMDEB was 2.75 mm (diameter) × 10 mm (length). The 
dimensions were pertinent to be deployed at rabbit iliac artery. The amount of drug coating was 260 µg equally 
for both DEB and LMDEB. The drug was uniformly coated with 3 µm thickness. The coating thickness was con-
firmed by energy dispersive x-ray spectroscopy (EDS) analysis by tracking chlorine (Cl) ion, which exists only in 
paclitaxel coating matrix (Fig. 3). LMDEB was uniformly coated with drug along both the smooth and micro-pat-
terned profiles of LMDEB surface. Pleating and folding processes were performed to prepare LMDEBs for their 
interventional application by reducing balloon profile.
Dependency of drug stamping on contact pressures. To prove our hypothesis that higher contact 
pressure enhances drug transfer from a DEB surface to endothelium, ex vivo tests were performed with harvested 
fresh endothelium samples. RB-coated DEB stamps were prepared and they were stamped on the endothelium 
tissue samples under contact pressures ranging from 1 to 10 kPa. Then, the distribution and the degree of infiltra-
tion of RB within ex vivo tissues were analyzed by confocal microscopic analysis. The fluorescent RB signals from 
each stamped tissue sample were quantified using the NIH ImageJ program by introducing integrated density 
(ID). The ID values were calculated from the fluorescent drug signals to quantify the drug distribution in the 
stamped endothelium tissue samples. We measured the ID of each sample from X- and Y-axis projection images 
of Fig. 4A–C. The fluorescent RB signal was stronger for the samples stamped under higher contact pressures 
(Fig. 4D). This indicates a strong correlation between the amount of drug delivered to the tissue samples and the 
contact pressure. Interestingly, the depth of drug dispersion into the tissue sample also showed strong depend-
ency on the contact pressure. The samples exposed to the contact pressure of 1 kPa showed a shallow depth of 
drug dispersion (below 10 µm), while the drug molecules reached down to the depths of about 20 and 50 µm, 
respectively, in the samples exposed to 5 and 10 kPa. This result indicates the direct dependency of drug delivery 
efficiency on the contact pressure between the drug-coated DEB surfaces and vascular tissue.
Contact pressure in vascular tissue surface by LMDEB vs. DEB. In order to further confirm our 
hypothesis, we conducted a finite element method (FEM) analysis to compare the contact pressures generated by 
LMDEB and conventional DEB in contact with the luminal vessel wall by simulating the environment of balloon 
inflation drug intervention. As shown in Fig. 5A and B, the contact region of vascular tissue has higher stress 
Figure 2. (A) Cross-sectional view of a micro-machined mold with an inset showing a non-machined mold 
for conventional drug eluting balloons (DEBs). (B) Cross-sectional view of LMDEB when fully inflated. The 
LMDEB has 16 conformal linear micro-patterns of 130 µm height with an inset showing lateral view. All scale 
bars indicate 1 mm.
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values (red color indicates higher stress) than other regions. Figure 5C shows the contact pressure distributions 
of the cyclic symmetry section, ranging from 0 to 22.5 degree, for the two different cases. If the diameters of 
DEB and LMDEB increase up to 2.75 mm, the maximum contact pressures at the artery surface increase up to 
Figure 3. Drug coating of (A) DEB and (B) LMDEB. Both thicknesses of drug coating and formed of either 
LMDEB or DEB are identical to about 3 µm and 25 µm. All scale bars indicate 10 µm.
Figure 4. Dependency of drug stamping on contact pressures. Laser scanning fluorescent confocal image of 
tissue samples stamped under contact pressure of (A) 1 kPa, (B) 5 kPa, and (C) 10 kPa. (D) Comparative plot of 
integrated density (ID) from ex vivo tissues with contact pressure applied in range of 1 to 10 kPa. All scale bars 
indicate 50 µm.
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0.079 MPa and 0.631 MPa for DEB and LMDEB, respectively. The maximum contact pressure of LMDEB is eight 
times higher than that of DEB.
In this FEM analysis, the LMDEB and DEB are assumed to be inflated uniformly in a radial direction. 
However, the inflation process of the balloons in clinical situations is slightly different from the simulated process. 
In a clinical situation, a DEB is folded and rolled up to be inserted into a catheter, and it is delivered to a target 
lesion through tortuous blood vessels. Then, the balloon is unrolled and unfolded during balloon inflation. The 
inflation process was omitted for the FEM simulation since the inflation took only a couple of seconds, compared 
to the contact time of 60 seconds. Thus, the FEM analysis focused on the final contact step for 60 seconds for drug 
delivery instead of modeling the entire process of balloon inflation.
Drug distribution in vascular tissue by LMDEB vs. DEB. In order to confirm enhanced drug delivery 
of LMDEBs that can apply higher contact pressure than DEBs with flat surfaces, in vivo studies were performed 
on the left and right iliac arteries of rabbits using LMDEBs and DEBs. They were coated with model drugs, 
rhodamine B (RB) (n = 7) or a mixture of fluorophore (FP)-labeled PTX and pure PTX, PTX + FP, (n = 5). The 
formulation of PTX + FP was especially used in this study for more accurate prediction of drug distribution 
within the tissue by eliminating the property difference between RB and PTX. LMDEB and DEB interventions 
were performed at target sites, and no embolism, which could be induced by the fragments of drug coating, was 
observed throughout the entire study. After the interventions with the DEBs and LMDEBs, the treated vessels 
were harvested after 48 hours. The fluorescent signals of the model drugs were visualized after cryo-sectioning the 
harvested samples to preserve the distribution of the fluorescent signals, which are significantly altered during a 
long preparation process of paraffin-sectioning (Supplementary Data Figure S1).
As shown in Fig. 6A and B, fluorescent microscopic analysis was performed to detect drug distribution within 
vascular tissue treated with model drugs. All the conditions of image acquisition such as light intensity (6), expo-
sure time (1 second), and sensitivity to light (ISO 100) were maintained identical throughout the analysis. For 
Figure 5. (A) Contact interaction of LMDEB and vascular tissue when LMDEB is fully expanded to the 
diameter of 2.75 mm. (B) Finite element model in a contact region. Red color indicates higher stress. (C) 
Contact pressure distribution along the artery surface of the cyclic symmetry section ranging from 0 to 22.5 
degree.
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both RB and PTX + FP coatings, LMDEB treated samples showed higher fluorescent signals of the model drugs 
than DEB treated samples. This result demonstrates that drug can be delivered more effectively to the endovas-
cular tissue by LMDEBs than DEBs. To compare and analyze the drug distribution quantitatively, the ID of each 
fluorescent image was measured and then normalized by each sectional area of the vessel sample at the pixel scale. 
The normalized integrated densities (NIDs) of LMDEB (left artery) and DEB (right artery) tissue samples were 
compared with each other, as shown in Fig. 6C. It is shown that LMDEB has 2.84 (±0.71) times higher NID of RB 
than DEB, while LMDEB has 1.73 (±0.09) times higher NID of PTX + FP than DEB.
Quantification of drug amount transferred to vascular tissue. To quantitatively assess drug amount 
delivered to target vascular tissue, the amounts of drug residue within the vessels were measured by tissue homog-
enization and liquid chromatography mass spectrophotometry (LC/MS) analysis. The left (LMDEB) and right 
(DEB) iliac arterial tissues from 5 rabbits were harvested after 48 hours following balloon dilatation, and then 
the cultured tissues were homogenized and filtered in the liquid form. The PTX amounts in these liquid samples 
were quantified by LC/MS analysis. The result (Fig. 6D) indicates that DEB treated tissues retained 3.67 (±1.24) 
µg of PTX on average, while LMDEB treated tissues retained 8.43 (±0.89) µg of PTX. The detected amounts of 
PTX retained in tissue after 48 hours of balloon inflation are both 1.4% and 3.2% of drug coated on the surfaces 
of DEBs and LMDEBs, respectively. These results strongly support that LMDEBs transfer drug more efficiently to 
vascular tissue than DEBs with flat surfaces.
Therapeutic effect of LMDEB vs. DEB in atherosclerosis model. To demonstrate the enhanced 
efficacy of LMDEB, we performed in vivo tests with a vascular disease model. An atherosclerosis model was 
employed using rabbits whose iliac arteries were balloon injured after fed a high fat diet for five weeks. Balloon 
injured rabbits were treated under the same condition as described above. Both DEBs and LMDEBs were coated 
with 260 µg of PTX. There were four groups in this study as follows: negative control group (normal rabbit, n = 4), 
positive control group (atherosclerosis model, n = 8), LMDEB treated group (atherosclerosis model, n = 6), DEB 
Figure 6. (A) Microscopic images of rhodamine B (RB) distribution in vessels treated with LMDEB and 
DEB. Upper images are unstained optical images and below images are the corresponding fluorescent images. 
(B) Microscopic images of paclitaxel conjugated green fluorophore (PTX + FP) distribution in treated 
vessels treated with LMDEB and DEB. Upper images are unstained optical images and below images are 
the corresponding fluorescent images. (C) Normalized integrated density (NID) ratios of LMDEB/DEB for 
RB (n = 7) and PTX + FP (n = 5). *p < 0.001. (D) Residual amount of PTX remained in vessels treated with 
DEB and LMDEB (n = 5). All scale bars indicate 500 µm. *p < 0.05, compared with DEB group. All data were 
presented as the mean ± SEM.
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treated group (atherosclerosis model, n = 6). Quantitative coronary angiography (QCA) and optical coherence 
tomography (OCT) were performed immediately after balloon inflation and after 4 weeks. The progress of intimal 
formation was quantitatively analyzed in terms of diameter stenosis (DS) and area stenosis (AS). After the 4-week 
follow-up study, all vascular tissues were harvested and stained with trichrome and hematoxylin and eosin (H&E) 
for histological analysis to analyze vascular integrity and intimal formation.
First, the degree of intimal formation was investigated from proximal, mid, to distal sections at 3.3 mm 
intervals. Significant intima proliferation was observed in the positive control group, as expected (Fig. 7A). The 
stenosis progress in each group was quantified by measuring medial area, intimal area, and plaque area as fol-
lows: 1) media = external elastic lamina − internal elastic lamina, 2) intima = internal elastic lamina − lumen, 3) 
plaque = media + intima. Then intima-plaque ratio (I/P), which indicates the degree of intimal formation with 
Figure 7. (A) Histopathological (trichrome stained), optical coherence tomography (OCT), and quantitative 
coronary angiography (QCA) images of vessels treated with positive, negative, DEB, and LMDEB. The samples 
were stained with trichrome. All scale bars indicate 500 µm. (B) Intima to plaque ratios of positive group: 
63.04 ± 3.39%, negative group: 1.31 ± 0.57%, DEB group: 50.4 ± 2.86% and LMDEB group: 45.58 ± 4.19%.
(p = 0.001 by ANOVA), (C) Percentage of diameter stenosis (DS) of positive group (n = 4): 35.7 ± 2.81%, 
negative group (n = 8): 6.10 ± 1.37%, DEB group (n = 6): 30.47 ± 6.16%, and LMDEB group (n = 6): 
22.65 ± 6.77% (p = 0.002 by ANOVA), (D) Percentage of area stenosis (AS) of positive group: 51.78 ± 5.27%, 
negative group: 10.08 ± 0.91%, DEB group: 43.95 ± 6.60% and LMDEB group: 38.33 ± 5.32% (p = 0.007 by 
ANOVA). All data were presented as the mean ± SEM. *p < 0.05, compared with positive group. †p < 0.05, 
compared with negative group.
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respect to the thickness of a normal media layer, was calculated. As shown in Fig. 7B, intimal layer thickness was 
significantly decreased in both DEB and LMDEB treated groups than in the positive control group.
DS and AS values were estimated from quantitative angiography and OCT analysis by detecting the whole 
length of vessel lesion, where PTX was delivered (Fig. 7A). Mean radial diameter (RD) and minimal lumen 
diameter (MLD) were calculated with QCA. DS was defined as the following formulation: DS (%) = (mean 
RD − MLD)/mean RD × 100. In Fig. 7C, the DS of the LMDEB group substantially decreased compared to both 
positive and DEB groups. In particular, there was a statistically-significant difference between LMDEB and pos-
itive control groups. Although the DEB group had smaller DS values than the positive group, there was no sta-
tistical significance. On the other hand, the areas of lumen, plaque, and vessel were calculated by OCT image 
analysis for estimation of AS values for each group. The AS value was derived with the following formula: AS 
(%) = (vessel − lumen)/vessel × 100. As indicated in Fig. 7D, the AS of the LMDEB group was also smaller than 
both positive and DEB groups. In particular, there was a statistically significant difference between LMDEB and 
positive groups. However, no statistically significant difference was found between positive and DEB groups. 
(Detailed calculation of the experimentally measured values is given in Supplementary Data Figure S2).
Therapeutic effect of LMDEB vs. DEB in ISR model. We further investigated the therapeutic efficacy of 
LMDEB using an ISR model in minipigs. The ISR model was established by 4-week follow-up after stent implan-
tation, and the ISR presence was confirmed before ballooning with LMDEB or conventional DEB. The drug 
amounts and the dimensions of both LMDEB and conventional DEB were kept the same as when they were 
applied to the atherosclerotic model. Three devices of both LMDEBs and DEBs were used for drug delivery in 
total 6 ISR lesions. After 4 weeks, DS and AS were measured in each lesion by QCA and OCT analysis to deter-
mine the degree of lesion reduction.
As shown in Fig. 8A, ISR formed in all blood vessels of minipigs, and these lesions were treated with either 
LMDEBs or conventional DEBs. After 4 weeks, the ISR lesion treated with LMDEB was significantly reduced at 
the lumen side compared to the lesion treated with the conventional DEB (Fig. 8B). Both DS and AS of LMDEB 
group (n = 3) had smaller values than the DEB (n = 3) group with statistical significance. It is noteworthy that 
the LMDEB group had statistically predominant reduction in DS and AS compared to the DEB group. (Detailed 
calculation of the experimentally measured values is given in Supplementary Data Figure S3).
Discussions
Efficient drug delivery by DEBs has been reported to substantially reduce the occurrence rate of ISR16,19. DEB 
technologies have evolved rapidly by developing coating formulations or surface modification of DEBs for 
enhanced drug delivery. In addition, new drugs such as sirolimus or zotarolimus were introduced and their 
improved bioavailability and efficacy were demonstrated26,27. Different types of drug formulations to coat such 
limus-family drugs have also been developed using biodegradable polymer or nanoparticles28–30. However, this 
coating formulation-based approach strongly depends on the chemical properties of drugs, such as molecular 
weight or hydrophobicity, or on the properties of matrix materials used in the coating formulation. Although 
these characteristics of drug or drug formulation are likely to affect the drug retention rate within tissue, there 
are few studies that quantified the amount of drug residue so far. Furthermore, despite these rapid advances in 
drug coating/formulation as well as introduction of new drugs, DEB still suffers from significant drug loss during 
handling and application within vessels. Reduction in operation time of DEB application is also highly desired to 
minimize any side effect since blood flow is blocked during DEB treatments.
In this work, we demonstrated that higher contact pressure by micro-patterned DEBs enhanced transfer effi-
ciency of drug compounds to vascular tissue without changing drug coating/formulation. The mechanism of 
material transfer from a surface to another based on their contact has been studied for a long time. For example, 
the effect of contact speed and pressure on the quality and precision of printing were well described in the ink 
printing technology for newsprints. Increasing contact (printing) pressure increased the amount of transferred 
ink, whereas increased printing speed decreased the total transfer31. It was also reported that contact pressure 
needed to be above a certain level for direct contact between ink and a substrate depending on ink viscosity32. 
Mechanisms for material transfer between an ink and a substrate have also been explained by capillary immo-
bilization33 and ink transfer equation34. Since the first introduction of micro contact printing35, state-of-the art 
contact transfer technologies have been used in conventional gravure or letter printing as well as in metallic or 
organic electrode printing for flexible electrode36 or even protein printing for surface modification37. When it 
comes to development of advanced contact printing or transferring processes, the major factors are electrical 
and chemical surface characteristics of both stamp and ink for contact process as well as the ink and substrate 
of contact printing. However, moderate contact or impression is the precondition. In case of DEB development, 
there have been many studies for developing drug formulations with respect to their chemical and material char-
acteristics, but no study was performed to utilize contact pressure for enhanced drug delivery yet.
It is hypothesized that LMDEBs have “higher contact pressure after balloon inflation” for endovascular drug 
delivery compared to conventional DEBs. A conventional DEB expands and makes a uniform contact to the 
pre-stretched vessel diameter. On the other hand, the narrow ridges of a LMDEB make more localized contacts 
with the luminal side of the vessels. As confirmed in the FEM analysis results (Figs 1 and 5), this results in higher 
contact pressure to the contact regions, and this leads to more efficient drug delivery to vascular tissue. It was also 
shown that higher contact pressure led to deeper infiltration of drug from the endothelium to the media layer of 
vascular tissue. Since blood flow is highly viscous and fast, such deeper drug delivery into the target tissue can 
minimize any potential loss of drug to blood streams. This deeper drug delivery to vascular tissue at each LM, in 
turn, increases the retention rate of drug and lengthens the duration of the efficacy.
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With regard to the surface area of both DEBs and LMDEBs, the drug coated area of LMDEB (1 cm2) is 1.16 
times larger than that of conventional DEB (0.86 cm2). This increased surface area of LMDEBs can also contribute 
to the enhanced delivery of drug molecules to the vascular tissue. However, since more than 200% higher amount 
of residual PTX was measured in LMDEB-treated tissue samples (Fig. 6D), the contribution of the increased sur-
face area to the enhanced drug delivery is relatively small compared to the contribution of the increased contact 
pressure. Moreover, when blood vessel is fully stretched, actual contact between an LMDEB and the vascular 
tissue is likely to be limited to the small ridge area of the LMDEBs. This indicates that the increased surface area 
of LMDEB is not a major factor for enhanced drug delivery of LMDEB. On the other hand, the FEM analysis 
results showed 8 times higher contact pressure of LMDEBs than DEBs. Although further experimentation and 
analysis need to be performed with regard to the effect of the contact pressure and the surface area, this strongly 
suggests the main enhancement is originated from the higher contact pressure rather than the increased surface 
area of LMDEBs. Diseased vessels with ISR have non-uniform mechanical properties within the lesion due to the 
progress of stenosis and stents embedded at the site, which could be another factor in preventing uniform and 
reliable contact of DEB. The outcomes from our in vivo studies indicated that LMDEBs had enhanced delivery 
efficiency and therapeutic efficacy than DEBs, and this can be ascribed to deeper drug delivery by higher contact 
pressure as well as more uniform and reliable contacts even with ISR tissue.
We have developed LMDEB for enhanced drug delivery for ISR treatment. Ridge-shaped linear micro-patterns 
were formed on the surface of medical balloons by a blow-molding process for higher contact pressure during 
balloon inflation. The result of FEM analysis confirmed that the contact pressure of LMDEBs is higher than that 
of DEBs without any pattern. Ex vivo drug stamping tests also showed that higher contact pressure enhanced drug 
delivery to the luminal surface of blood vessels. In vivo studies with fluorescent and LC/MS analyses confirmed 
significantly higher drug delivery efficiency of LMDEBs than DEBs. Finally, in vivo efficacy tests were performed 
Figure 8. (A) QCA image indicating in-stent restenosis (ISR) modeling in minipig after 4 weeks stent 
implantation (4 insets on the left) and OCT image indicating therapeutic effect for ISR after 4 weeks balloon 
angioplasty (2 insets on the right). Scale bar indicates 1 mm. (B) Percentage of DS and AS of DEB (n = 3) and 
LMDEB (n = 3) groups; 34.67 ± 17.95% (DS, DEB group), 16.66 ± 3.56% (DS, LMDEB group), 60.39 ± 15.76% 
(AS, DEB group), 43.14 ± 6.40% (AS, LMDEB group). All data were presented as the mean ± SEM. * p < 0.05, 
compared with DEB group.
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using atherosclerotic rabbit and ISR minipig models, and demonstrated statistically-significant therapeutic effi-
cacy of LMDEBs compared to conventional DEB of LMDEBs.
Methods
Molding process for LMDEB and drug coating. LMDEBs were fabricated using a blow-molding pro-
cess identical to a conventional DEB manufacturing process with customized balloon forming molds. Brass bal-
loon forming molds were 10 mm long with the diameter of 2.75 mm. They had 16 intaglii LMs (300 µm depth) 
that were patterned the inside of a cylindrical mold by EDM wire-cut (Fig. 2A). The finished custom molds 
were installed in a balloon forming machine. A PEBAX cylinder tube (inner diameter: 0.60 mm, outer diameter: 
1.00 mm) (Arkema, France) was placed in alignment to the center axis of the mold. The PEBAX tube was heated 
up to 130 °C and high pressure Ar gas at 30 bars was injected into the heated tube such that the tube expanded 
and formed a balloon. Upon completion of the molding process, the balloon and mold were rapidly cooled down 
to room temperature.
Then, the fabricated LMDEBs were folded to have three wings and flow-coated with a pipette using natural 
hydrophilic polymer coating formulation similar to PACCOCATH technology. RB (R6626, Sigma Aldrich, USA), 
PTX (P9600, LC Laboratories, USA) and the mixture of PTX labeled with a fluorescent molecule, Oregon Green 
488 (P22310, Molecular Probes, USA), and pure PTX (w/w = 1:1000) (PTX + FP) were used for drug coating 
in this study. Finally, the drug coated balloons were assembled with catheter sheath and rolled up to reduce the 
balloon profile. After drug coating of the balloons, the cross-section of the balloon was examined to measure the 
thickness and uniformity of drug coating by tracking chlorine using an EDS equipped scanning electron micro-
scope (JEOL 7800 F, JEOL, USA). The EDS analysis was carried out at ×2000 magnification and under 15 kV 
accelerated voltage.
Effect of contract pressure on drug stamping. To understand how contact pressure affects the delivery 
efficiency of drug from DEB surfaces to vascular tissue, we performed ex vivo drug stamping test by varying con-
tact pressures from 1 to 10 kPa. A portion of a DEB coated with RB was cut and attached to the bottom side of a 
square-shaped metal bar (4 × 4 mm2). This RB-coated DEB stamp was installed to an auto micro-stage for precise 
control of drug stamping. Harvested samples of rabbit femoral artery were fixed on a load cell with its lumen side 
up to have a direct contact with the stamp. Contact pressures of 1, 5, and 10 kPa were applied to each artery sam-
ple for 60 seconds. Then, these samples were stored in a sealed chamber under 100% humidity at 4 °C for 12 hours. 
The amount and distribution of the model drug, RB, within each artery tissue sample, was assessed using a fluo-
rescent confocal microscope (LSM700, Zeiss, Germany). The pictures of all samples were taken under identical 
imaging conditions (exposure time, gain, filter). The 3D images for overall drug distribution and 2D orthogonal 
images from x- and y-axis projection for precise depth of drug infiltration were visualized by an image analyzer 
program (Zen 2011, Zeiss, Germany). To analyze drug distribution in the vascular tissue, the IDs of delivered RB 
within the tissue were quantitatively analyzed using ImageJ software (National Institutes of Health, USA) from 
the 2D orthogonal images according to the method previously described38.
FEM simulation for contact pressure analysis. In order to estimate the contact pressure at LM, FEM 
analysis was performed using ABAQUS to investigate the effect of the LMs of LMDEB on the contact pressure 
between LMDEB and the luminal surface of vascular tissue. The finite element model was assumed to be a plane 
strain state since the longitudinal length is relatively longer than the diameter of LMDEB. The material properties 
such as the modulus of elasticity and the Poisson’s ratio of LMDEB and the vascular tissue of rabbit femoral artery 
were 500 MPa, 0.1 and 3.50 MPa, 0.3, respectively. The finite element model has sufficiently refined meshes that 
have 20 contact nodes in any contact region. The model has 52,627 plane strain elements, with a total of 57,071 
nodes (Fig. 5B). The contact condition between LMDEB and artery was assumed to be frictionless. A displace-
ment was applied to the compressed LMDEB in the radial direction and is gradually increased until LMDEB was 
fully expanded to the diameter of 2.75 mm, as shown in Fig. 5A.
In vivo tests with rabbit model. A total of 26 male New Zealand White rabbits (3.5–4.0 kg weight) were 
used in this study (12 rabbits for the drug distribution test. and 14 rabbits for the efficacy test in Section 3.6). All 
rabbits were acclimatized for a week, housed at room temperature with a 12-hour cycle with free access to stand-
ard diet and water. The study protocol was approved by the local Institutional Animal Care and Use Committee of 
Yonsei University Health System (IACUC: 2015–0028 and Cardiovascular Production Evaluation Center, Yonsei 
University College of Medicine). All animals received human care in compliance with the Animal Welfare Act 
and the “Principles of Laboratory Animal Care” formulated by the Institute of Laboratory Animal Resources 
(National Research Council, NIH Publication No. 85–23, revised 1996).
After premedication with antibiotics and analgesics, anesthesia was induced by intramuscular injection with 
an appropriate Zoletil (10 mg/kg, Virvac, USA) and Rompun (5 mg/kg, Bayer, Germany), then maintained with 
2–3% of isoflurane (Forane®, JW Pharm, Republic of Korea) and oxygen. Access to the iliac artery was obtained 
via the carotid artery, using a sterile surgical technique. Heparin (150 units/kg) was injected to maintain an acti-
vated clotting time within 250 seconds before catheterization. Rabbits for atherosclerosis model were injured with 
inflated balloons after fed a high cholesterol diet (1% cholesterol, DooYeol Biotech, Republic of Korea). During 
the intervention procedure, oversized balloon inflation with 1.3:1.0 balloon-artery ratio was performed one time 
for 30 seconds within both iliac arteries (right and left). Then, conventional DEB (right iliac) (Genoss Co., Ltd., 
South Korea) and LMDEB (left iliac) were applied to the vessels for 60 seconds at iliac arteries. In the experiment 
to investigate drug distribution and efficiency of LMDEB, 14 normal rabbits were used with both LMDEB and 
conventional DEB coated either RB or PTX + FP as a model drug. The balloon inflation conditions are the same 
as before. All rabbits received aspirin (40 mg/kg) and clopidogrel (75 mg/daily) at the end of the procedure.
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In vivo tests with ISR minipig model. A total of 2 male minipigs, aged 6 months, weighing 35 kg were 
used in the study. The study protocol was also approved by Yonsei University’s IACUC (2016–0028) as described 
previously. All the pigs were given antiplatelet pretreatment with aspirin (10 mg/kg) and clopidogrel (75 mg/
daily) as well as antibiotics and analgesics. Anesthesia was induced by intramuscular injection with an appropriate 
mixture of Zoletil and Rompun, then maintained with 1.5% of isoflurane and oxygen. Heparin (200 units/kg) was 
injected to maintain an activated clotting time within 250 seconds before catheterization.
Two right coronary arteries (RCA), left anterior descending arteries (LAD) and left circumflex arteries (LCX), 
respectively, total 6 coronary arteries of 2 minipigs were blinded to the randomization assignment and divided 
into 2 groups; conventional DEB (n = 3) and LMDEB (n = 3). Access to the coronary artery was obtained via the 
carotid artery using the sterile surgical technique. Oversized balloon inflation with a 1.3:1.0 balloon-artery ratio 
was repeated twice for 30 seconds each, followed by implantation of a 3 mm (length) × 18 mm (diameter) stent in 
each major coronary artery. We reconfirmed balloon inflation pressure to achieve the desired overstretching by 
angiography. 4 weeks after the procedure we confirmed ISR formation in the minipig model by OCT and QCA 
analysis. These two ISR induced minipigs were treated by balloon inflation for 60 seconds with conventional 
DEBs or LMDEBs coated with PTX by following the same procedure as described above in the in vivo tests with 
rabbit models. After 4 weeks, OCT and QCA were performed, and euthanasia was carried out to harvest coronary 
arteries.
Fluorescence and histologic image analysis. For fluorescent analysis to visualize drug distribution, 
target vessels were cryo-sectioned. Harvested tissue samples were immediately embedded in optimum cutting 
temperature compound (Tissue-Tek, Sakuta Finetek, USA) and frozen with dry ice. Frozen samples were sec-
tioned with a microtome at 10 µm thickness, and then images were taken using a fluorescent microscope (BX53, 
Olympus, Japan) under identical imaging condition (light intensity = 6, exposure time = 1 second, sensitiv-
ity = ISO 100). The images were analyzed with an image analyzer program (DP Controller, Olympus, Japan). 
Afterwards, the fluorescent intensities of these sample images were calculated by measuring the ID as described 
previously. Since the sectional area of the blood vessel varies from sample to sample, the measured value was 
normalized by the area of the blood vessel to obtain normalized integrated density (NID).
For therapeutic efficacy analysis, target vessels were paraffinized and stained. Cultured vascular samples were 
fixed by continued perfusion with 10% normal buffered formalin for a day. For paraffin embedding, a 5 mm long 
sample of the vessel was placed intactly into a single cassette and processed through a graded series of alcohols 
and xylenes, and then the specimens were embedded in a single paraffin block. Paraffinized samples were sec-
tioned with a microtome at 4 µm thickness, mounted on silane-coated slides, and stained with hematoxylin and 
eosin (H&E) (Merck, Darmstadt, Germany), Masson’s trichrome (BBC Biochemical, USA). The cross-sectional 
area was measured using an optical microscope (SCN400, Leica, Germany) and histomorphometry was per-
formed using LAS 4.2 software.
LS/MS measurement of drug residue in vascular tissue. The target vascular lesions treated with DEB 
or LMDEB were harvested after 2 days by sacrificing the rabbits with potassium injection. The harvested tissue 
samples soaked in 200 µl mixture of methanol and acetonitrile (J.T. Baker® Chemicals, USA) (w/w = 1:1) were 
pulverized using a sonicator (Q500, Qsonica, USA) and mixed with a mixing block (MB-102, BioER, China) for 
30 minutes. A standard curve was prepared at 0.01, 0.1, 0.5, 1, and 5 ppm. All sample aliquots were transferred 
into autosampler vials at 10 µl. The PTX concentrations of the homogenates were quantified through an LC/MS 
system (Agilent 6530 Accurate-Mass Q-TOF LC/MS, Agilent Technologies, USA). The flow rate of LC/MS was 
0.5 ml/min through a column of extend C-18 (Agilent Technologies, USA). The mobile phase was the mixture of 
methanol and acetonitrile (w/w = 1:1). PTX in the aliquots was detected by the mass spectrometry in multiple 
reaction-monitoring modes with a transition of PTX from 876.3218 AMU.
Vascular stenosis evaluation. The degree of stenosis was assessed over the entire 10 mm length of treated 
vessel following DEB and LMDEB intervention. QCA and OCT were performed immediately after balloon infla-
tion and after 4 weeks to monitor the progress of intimal formation in terms of DS and AS. OCT was operated 
using a C7-XR imaging system (LightLab Imaging Inc., St. Jude Medical, USA). Contrast media was constantly 
flushed at a flow rate of 4 mL/s through a guiding catheter for 4 seconds. The OCT catheter was pulled back at 
a rate of 20 mm/s, and the OCT image acquisition frequency was 100 frames/s. All OCT images were analyzed 
at an independent core laboratory (Cardiovascular Research Center, Republic of Korea) by analysts blinded to 
procedural information. The histological images were compared to the proximity to side branches, and the length 
from the balloon injury edge to the location of the histology samples (provided by the histological laboratory).
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